Flexible Expansion: Meeting Evolving Needs in Oncology & Immunology
download Read now!
Whitepaper
Explore how new capabilities and capacities will open doors to innovation.
BSP Pharmaceuticals is expanding their operations with a €320 million plan that significantly increases their ability to develop and produce vital oncology and immunology therapeutics.
Discover what the plan includes and how it will meet the needs of cytotoxic and high potent oncology drugs and non-cytotoxic (up to OEB 6) innovative compounds for immunotherapy.
Explore BSP’s plans for:
- Expanded drug substance (DS) and drug product (DP) capacity
- More flexible manufacturing capabilities
- Support for end-to-end antibody-drug conjugates (ADC) requirements
- The addition of key analytical capabilities for new technologies
- Investment plans to support clients’ strategic growth over time
To download your free white paper, simply complete the form!
By completing this form you agree BSP Pharmaceuticals and Citeline may contact you directly about industry news, products, services and events that may be of interest. This is subject to BSP Pharmaceutical privacy policy and Citeline’s privacy policy.
Inspire. Connect. Innovate.
